- Home
- BEAM vs GAM Comparison
BEAM vs GAM Comparison
Compare BEAM & GAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- GAM
- Stock Information
- Founded
- BEAM 2017
- GAM 1927
- Country
- BEAM United States
- GAM United States
- Employees
- BEAM N/A
- GAM N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- GAM Investment Managers
- Sector
- BEAM Health Care
- GAM Finance
- Exchange
- BEAM Nasdaq
- GAM Nasdaq
- Market Cap
- BEAM 1.7B
- GAM 1.5B
- IPO Year
- BEAM 2020
- GAM N/A
- Fundamental
- Price
- BEAM $25.79
- GAM $62.51
- Analyst Decision
- BEAM Strong Buy
- GAM
- Analyst Count
- BEAM 11
- GAM 0
- Target Price
- BEAM $49.40
- GAM N/A
- AVG Volume (30 Days)
- BEAM 2.3M
- GAM 20.1K
- Earning Date
- BEAM 11-04-2025
- GAM 01-01-0001
- Dividend Yield
- BEAM N/A
- GAM 5.74%
- EPS Growth
- BEAM N/A
- GAM N/A
- EPS
- BEAM N/A
- GAM 11.67
- Revenue
- BEAM $60,272,000.00
- GAM N/A
- Revenue This Year
- BEAM N/A
- GAM N/A
- Revenue Next Year
- BEAM $18.95
- GAM N/A
- P/E Ratio
- BEAM N/A
- GAM $3.95
- Revenue Growth
- BEAM N/A
- GAM N/A
- 52 Week Low
- BEAM $13.53
- GAM $37.32
- 52 Week High
- BEAM $35.25
- GAM $46.48
- Technical
- Relative Strength Index (RSI)
- BEAM 57.00
- GAM 56.81
- Support Level
- BEAM $23.53
- GAM $62.31
- Resistance Level
- BEAM $28.75
- GAM $63.98
- Average True Range (ATR)
- BEAM 1.76
- GAM 0.91
- MACD
- BEAM -0.13
- GAM -0.14
- Stochastic Oscillator
- BEAM 50.50
- GAM 35.06
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About GAM General American Investors Inc.
General American Investors Co Inc is a closed-end, diversified management investment company. The primary investment objective of the company is long-term capital appreciation through investment in companies with above-average growth potential. It focuses on equity securities with growth potential at reasonable valuations.